CVT-6883, formerly known as GS6201 is a selective A2B adenosine antagonist, represents a potential approach to treating cardiopulmonary diseases. A pre-clinical study showed that CVT-6883 significantly reduced elevated markers of inflammation, fibrosis and pulmonary injury in in vivo preclinical models. References: Ortore G, Martinelli A. A2B receptor ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):923-40. Review. PubMed PMID: 20370659.

纯度：≥98%

CAS：752222-83-6